Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L. Saraf, Ana Maria Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli

Blood (2023) 142 (Supplement 1): 4897.

https://doi.org/10.1182/blood-2023-179270

Published: 2023

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma

Pritesh R. Patel, MB, ChB, Annie L. Oh, MD, Matthew Koshy, MD, Bulent Aydogan, PhD, Karen Sweiss, PharmD, John G. Quigley, MD, Santosh L. Saraf, MD, Irum Khan, MD, Eileen D. Hacker, PhD APN, AOCN, Nadim Mahmud, MD PhD, David J. Peace, MD, Howard Ozer, MD PhD, Jennifer Windhorst, APN, Ralph R Weichselbaum, MD, Damiano Rondelli, MD

Blood (2016) 128 (22): 4646.

https://doi.org/10.1182/blood.V128.22.4646.4646

Published: 2016

Journal Articles

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Pritesh R. Patel, MB, ChB, Annie L. Oh, MD, Matthew Koshy, MD, Bulent Aydogan, PhD, Nadim Mahmud, MD, PhD, David Peace, MD, John G. Quigley, MD, Santosh L. Saraf, MD, Enzo DeMasi, MD, Ralph R Weichselbaum, MD, Damiano Rondelli, MD

Blood (2013) 122 (21): 3285.

https://doi.org/10.1182/blood.V122.21.3285.3285

Published: 2013

Journal Articles

Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.

Pritesh R. Patel, MB, ChB, Bulent Aydogan, PhD, Damiano Rondelli, MD

Blood (2010) 116 (21): 4526.

https://doi.org/10.1182/blood.V116.21.4526.4526

Published: 2010

NARROW

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.

Email alerts

ASH Publications

American Society of Hematology

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

A Phase 1 Study of Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/ Refractory Multiple Myeloma

Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study

Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only